165 related articles for article (PubMed ID: 15225251)
1. Different susceptibility of B19 virus and mice minute virus to low pH treatment.
Boschetti N; Niederhauser I; Kempf C; Stühler A; Löwer J; Blümel J
Transfusion; 2004 Jul; 44(7):1079-86. PubMed ID: 15225251
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses.
Mani B; Gerber M; Lieby P; Boschetti N; Kempf C; Ros C
Transfusion; 2007 Oct; 47(10):1765-74. PubMed ID: 17880601
[TBL] [Abstract][Full Text] [Related]
3. Studies on the inactivation of human parvovirus 4.
Baylis SA; Tuke PW; Miyagawa E; Blümel J
Transfusion; 2013 Oct; 53(10 Pt 2):2585-92. PubMed ID: 24032592
[TBL] [Abstract][Full Text] [Related]
4. Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability.
Ros C; Baltzer C; Mani B; Kempf C
Virology; 2006 Feb; 345(1):137-47. PubMed ID: 16242744
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
7. Inactivation and neutralization of parvovirus B19 Genotype 3.
Blümel J; Rinckel LA; Lee DC; Roth NJ; Baylis SA
Transfusion; 2012 Jul; 52(7):1490-7. PubMed ID: 22339291
[TBL] [Abstract][Full Text] [Related]
8. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
9. Adaptive immune responses against parvovirus B19 in patients with myocardial disease.
Lindner J; Noutsias M; Lassner D; Wenzel J; Schultheiss HP; Kuehl U; Modrow S
J Clin Virol; 2009 Jan; 44(1):27-32. PubMed ID: 18980860
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
Sawyer L; Hanson D; Castro G; Luckett W; Dubensky TW; Stassinopoulos A
Transfusion; 2007 Jun; 47(6):1062-70. PubMed ID: 17524098
[TBL] [Abstract][Full Text] [Related]
11. Discovery and analysis of a novel parvovirus B19 Genotype 3 isolate in the United States.
Rinckel LA; Buno BR; Gierman TM; Lee DC
Transfusion; 2009 Jul; 49(7):1488-92. PubMed ID: 19389024
[TBL] [Abstract][Full Text] [Related]
12. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.
Azzi A; Maggi F; Zakrzewska K; Menconi MC; Di Pietro N; Salotti V; Farina C; Andreoli E; Fiorentino B; Angelini C; Corcioli F; Bendinelli M
Transfusion; 2006 Jul; 46(7):1162-7. PubMed ID: 16836563
[TBL] [Abstract][Full Text] [Related]
13. Stability of minute virus of mice against temperature and sodium hydroxide.
Boschetti N; Wyss K; Mischler A; Hostettler T; Kempf C
Biologicals; 2003 Sep; 31(3):181-5. PubMed ID: 12935806
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types.
Schleh M; Romanowski P; Bhebe P; Zhang L; Chinniah S; Lawrence B; Bashiri H; Gaduh A; Rajurs V; Rasmussen B; Chuck A; Dehghani H
Biotechnol Prog; 2009; 25(3):854-60. PubMed ID: 19405099
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.
Modrof J; Berting A; Tille B; Klotz A; Forstner C; Rieger S; Aberham C; Gessner M; Kreil TR
Transfusion; 2008 Jan; 48(1):178-86. PubMed ID: 17900278
[TBL] [Abstract][Full Text] [Related]
16. Variability of parvovirus B19 to inactivation by liquid heating in plasma products.
Hattori S; Yunoki M; Tsujikawa M; Urayama T; Tachibana Y; Yamamoto I; Yamamoto S; Ikuta K
Vox Sang; 2007 Feb; 92(2):121-4. PubMed ID: 17298573
[TBL] [Abstract][Full Text] [Related]
17. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays.
Koppelman MH; Rood IG; Fryer JF; Baylis SA; Cuypers HT
Vox Sang; 2007 Oct; 93(3):208-15. PubMed ID: 17845257
[TBL] [Abstract][Full Text] [Related]
18. Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process.
Adamson-Small LA; Ignatovich IV; Laemmerhirt MG; Hobbs JA
Virus Res; 2014 Sep; 190():8-16. PubMed ID: 24998884
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
[TBL] [Abstract][Full Text] [Related]
20. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Hougardy V; de Launoit Y; Laub R
Transfusion; 2004 Sep; 44(9):1340-3. PubMed ID: 15318858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
